



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. GPO 0-805-0001
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

<p>For the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>					
			Complete if Known		
			Application Number	10/075,654	
			Filing Date	February 14, 2002	
			First Named Inventor	Charles Andrianjara	
			Group Art Unit	1624	
			Examiner Name	Deepak R. Rao	
Sheet	1	of	2	Attorney Docket Number	A0000477-01-CFP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Wyrak bay

Date
Considered

9/2/04

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


114. **Enter Office that issued the document, by the two-letter code.** **See attached Kinds of U.S. Patent Documents.**

1 Unique citation designation number. See attached *Kinds of U.S. Patent Documents*. Enter Office that issued the designation, by the date of issue, in the first line of the title.

code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the filing of the application is omitted.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

number of the patent document. **Kind of document** by the appropriate symbols as indicated on the document sheet. **11.3 Standard 3111-1994**
possible. **11.4** **English** **11.5** **Check** **mark** **here** **if** **English** **language** **Translation** **is** **attached**.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/075,654
Filing Date	February 14, 2002
First Named Inventor	Charles Andrianjara
Art Unit	1624
Examiner Name	Deepak R. Rao
Attorney Docket Number	A0000477-01-CFP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Office Action from 10/264,764 (PC20536A) mailed 6.16.03	
		PCT International Search Report, PCT/EP02/01961	
DR		LOVEJOY et al., "Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors", Nature Structural Biology, 1999, Vol. 6, No. 3, pages 217-221	
DR		MOY et al., "High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor", J. Mol. Biol., 2000, Vol. 302, 671-689	
DR		MITCHELL et al., "Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage", J. Clin. Invest., 1996, Vol. 97, No. 3, pages 761-768	
DR		NEUHOLD et al., "Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) reduces osteoarthritis in mice", J. Clin. Invest., 2001, Vol. 107, No. 1, pages 35-44	
DR		DAHLBERG et al., "Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritis Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase 1 (Matrix Metalloproteinase 1)", Arthritis & Rheum., 2000, Vol. 43, No. 3, pages 673-682	
DR		BILLINGHURST et al., "Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selection Inhibition of Type II Collagen Cleavage by Collagenase", Arthritis & Rheum., 2000, Vol. 43, No. 3, pages 664-672	
DR		BILLINGHURST et al., "Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage", J. Clin. Invest., 1997, Vol. 99, No. 7, pages 1534-1545	
DR		HIROTA et al., "Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative Coupling", Heterocycles, 1994, Vol. 37, No. 1, pages 563-570	

Examiner Signature	Deepak R. Rao	Date Considered	7/21/04
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.